Cost-Utility Analysis of First-Line Regimen Between Cisplatin Plus Pemetrexed and Carboplatin Plus Paclitaxel In Advanced Non-Squamous Non-Small-Cell Lung Cancer in Thailand

Cost-Utility Analysis of First-Line Pemetrexed Plus Cisplatin in Non-Small Cell Lung Cancer in Thailand

Value in Health Regional Issues ◽

10.1016/j.vhri.2019.04.005 ◽

2020 ◽

Vol 21 ◽

pp. 9-16 ◽

Cited By ~ 1

Author(s):

Unchalee Permsuwan ◽

Sumitra Thongprasert ◽

Buntitabhon Sirichanchuen

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Cost Utility ◽

Small Cell ◽

Cost Utility Analysis ◽

Utility Analysis ◽

Small Cell Lung ◽

PCN197 - COST UTILITY ANALYSIS OF FIRST-LINE PACLITAXEL WITH CARBOPLATIN AND BEVACIZUMAB FOLLOWED BY MAINTENANCE BEVACIZUMAB VERSUS PEMETREXED WITH CARBOPLATIN FOLLOWED BY MAINTENANCE PEMETREXED IN PATIENTS WITH ADVANCED NON-SQUAMOUS NON-SMALL-CELL LUNG CANCER IN LEBANON

Value in Health ◽

10.1016/j.jval.2018.09.279 ◽

2018 ◽

Vol 21 ◽

pp. S47

Author(s):

A. Tfayli ◽

F. Elias ◽

F. Farhat ◽

R. Slim ◽

Z. Hallal ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Cost Utility ◽

Small Cell ◽

Cost Utility Analysis ◽

Utility Analysis ◽

Small Cell Lung ◽

Addition of cetuximab to first-line chemotherapy in patients with advanced non-small-cell lung cancer: a cost–utility analysis

Annals of Oncology ◽

10.1093/annonc/mdq431 ◽

2011 ◽

Vol 22 (3) ◽

pp. 567-574 ◽

Cited By ~ 12

Author(s):

M. Joerger ◽

K. Matter-Walstra ◽

M. Früh ◽

U. Kühnel ◽

T. Szucs ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Cost Utility ◽

Small Cell ◽

Cost Utility Analysis ◽

Utility Analysis ◽

Small Cell Lung ◽

First Line ◽

Line Chemotherapy

Cost-Utility Analysis of First-Line Gefitinib, Erlotinib and Afatinib in Patients with Non-Small Cell Lung Cancer Harboring EGFR Mutations

Value in Health ◽

10.1016/j.jval.2016.09.2253 ◽

2016 ◽

Vol 19 (7) ◽

pp. A740-A741

Author(s):

MS Holleman ◽

R Zaim ◽

CA Uyl-De Groot

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Cost Utility ◽

Small Cell ◽

Cost Utility Analysis ◽

Egfr Mutations ◽

Utility Analysis ◽

Small Cell Lung ◽

Cost–Utility Analysis of Short- Versus Long-Course Palliative Radiotherapy in Patients With Non–Small-Cell Lung Cancer

JNCI Journal of the National Cancer Institute ◽

10.1093/jnci/djj496 ◽

2006 ◽

Vol 98 (24) ◽

pp. 1786-1794 ◽

Cited By ~ 42

Author(s):

Wilbert B. van den Hout ◽

Gijsbert W. P. M. Kramer ◽

Ed M. Noordijk ◽

Jan-Willem H. Leer

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Palliative Radiotherapy ◽

Cost Utility ◽

Small Cell ◽

Cost Utility Analysis ◽

Utility Analysis ◽

Small Cell Lung ◽

Long Course

PCN58 A COST UTILITY ANALYSIS OF ERLOTINIB IN PATIENTS WITH PREVIOUSLY TREATED ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC)

Value in Health ◽

10.1016/s1098-3015(10)70236-9 ◽

2008 ◽

Vol 11 (3) ◽

pp. A72 ◽

Cited By ~ 3

Author(s):

PA Bradbury ◽

R Jang ◽

P Isogai ◽

R Ng ◽

N Mittmann ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Cost Utility ◽

Small Cell ◽

Cost Utility Analysis ◽

Utility Analysis ◽

Small Cell Lung ◽

Previously Treated

Cost-utility of erlotinib combined with bevacizumab versus bevacizumab alone after completion of chemotherapy with bevacizumab for first-line treatment of advanced non-small-cell lung cancer

Journal of Chinese Pharmaceutical Sciences ◽

10.5246/jcps.2017.06.049 ◽

2017 ◽

Vol 26 (6) ◽

Author(s):

Yu Shuwen

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Cost Utility ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

PCN40 Cost-Utility Analysis of Pembrolizumab Versus Platinum Based Chemotherapy As the First-LINE Treatment for Advanced and Metastatic NON-SMALL CELL LUNG Cancer (NSCLC) in UK

Value in Health Regional Issues ◽

10.1016/j.vhri.2020.07.090 ◽

2020 ◽

Vol 22 ◽

pp. S12

Author(s):

J. Verma ◽

D. Verma ◽

A. Maria

Keyword(s):

Lung Cancer ◽

Cost Utility ◽

Small Cell ◽

Cost Utility Analysis ◽

Line Treatment ◽

Utility Analysis ◽

Small Cell Lung ◽

First Line ◽

Platinum Based Chemotherapy ◽

PCN53 Cost-Utility Analysis of Dacomitinib As First-LINE Treatment for Patients with Locally Advanced or Metastatic NON-SMALL CELL LUNG Cancer in China

Value in Health Regional Issues ◽

10.1016/j.vhri.2020.07.103 ◽

2020 ◽

Vol 22 ◽

pp. S15

Author(s):

G. Jin ◽

J. Zhao ◽

L. Yang

Keyword(s):

Lung Cancer ◽

Locally Advanced ◽

Cost Utility ◽

Small Cell ◽

Cost Utility Analysis ◽

Line Treatment ◽

Utility Analysis ◽

Small Cell Lung ◽

First Line ◽

Cost-utility of afatinib and gefitinib as first-line treatment for EGFR-mutated advanced non-small-cell lung cancer

Future Oncology ◽

10.2217/fon-2018-0692 ◽

2019 ◽

Vol 15 (2) ◽

pp. 181-191

Author(s):

Hao Wang ◽

Chenxin Zeng ◽

Xin Li ◽

Youjie Wang ◽

Xinyi Li ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Cost Utility ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Egfr Mutated ◽